| | | |
|---|---|---|
| CGFL CENTRE GEORGES FRANÇOIS LECLERC Ensemble, dépassons le cancer | **CRITERES DE SELECTION**<br><br>**ETUDE MK-7339-002-00 LYNK002** | Identité patient<br>(coller étiquette patient) |
| Version 1.0 du 10/03/2015 | Investigateur : | Arc : P. Philippe |

# VALIDATION DES CRITERES DE SELECTION

## Critères d'inclusion

| | |
|---|---|
| **1.**Participant has a histologically- or cytologically-confirmed advanced (metastatic and/or unresectable) solid tumor (except breast or ovarian cancers whose tumor has a germline or somatic BRCA mutation) that is not eligible for curative treatment and for which standard of care therapy has failed. Participants must have progressed on or be intolerant to standard of care therapies that are known to provide clinical benefit. There is no limit on the number of prior treatment regimens..<br>Note: Enrollment of participants who have received 3 or more prior lines of cytotoxic chemotherapy (as defined in Section 8.1.5.1.1) will be capped at approximately 20% of the total study population.. | ☐ oui ☐ non |
| **2.**Participant has either centrally-confirmed known or suspected deleterious mutations in at least 1 of the specified 15 genes involved in HRR (*ie, BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B,RAD51C, RAD51D, and RAD54L*) or centrally-confirmed HRD based on the Lynparza HRR-HRD assay. | ☐ oui ☐ non |
| **3.** If participants have received prior platinum (cisplatin, carboplatin, or oxaliplatin either as monotherapy or in combination) for advanced (metastatic and/or unresectable) solid tumor, they are eligible to enter the study provided there has been no evidence of disease progression during the platinum chemotherapy.<br>Note: Participants do not need to have received a previous platinum regimen to be considered eligible. | ☐ oui ☐ non |
| **4.** Participant has measurable disease per RECIST 1.1 or PCWG-modified RECIST 1.1 as assessed by the local site Investigator/radiology and confirmed by BICR. BICR must confirm the presence of radiologically measureable disease based on RECIST 1.1 or PCWG-modified RECIST 1.1 for the participant to be eligible for the study. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. | ☐ oui ☐ non |
| **5.** Participant is able to provide a newly obtained core or excisional biopsy of a tumor lesion or either an archival formalin-fixed paraffin embedded (FFPE) tumor tissue block or slides. A newly obtained biopsy is preferred, but not required if archival tissue is available for analysis. | ☐ oui ☐ non |

| | |
|---|---|
| Note: FFPE tumor blocks are preferred to slides. If submitting unstained cut slides, freshly cut slides should be submitted to the testing laboratory within 24 hours from the date the slides are cut (refer to Section 8.1.12.2). | |
| **6.**Participant has a life expectancy of at least 3 months. | ☐ oui ☐ non |
| **7.** Participant is Male or Female who is at least 18 years of age at the time of signing the informed consent | ☐ oui ☐ non |
| **8.** Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1, as assessed within 3 days of treatment initiation. | ☐ oui ☐ non |
| **Male Participants**<br>**9.** A male participant must agree to use contraception as detailed in Appendix 5 of this protocol during the treatment period and for at least 90 days (3 months), corresponding to time needed to eliminate any study intervention(s) (ie, olaparib) plus a spermatogenesis cycle, after the last dose of study intervention and refrain from donating sperm during this period. Refer to Appendix 5 for additional guidance. | ☐ oui ☐ non |
| **Female Participants**<br>**10.** A female participant is eligible to participate if she is not pregnant (Appendix 5), not breastfeeding, and at least 1 of the following conditions applies:<br>- Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.<br>OR<br>- A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during the treatment period and for at least 30 days (1 month) after the last dose of study intervention, corresponding to time needed to eliminate any study intervention(s) (ie, olaparib) plus 30 days (a menstruation cycle) for study interventions with risk of genotoxicity. | ☐ oui ☐ non |
| **Informed Consent**<br>**11.** The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for FBR. However, the participant may participate in the main study without participating in FBR. | ☐ oui ☐ non |
| **Additional Categories**<br>**12.** Participant has adequate organ function, as detailed in Table 3; all screening laboratory tests should be performed within 10 days prior to the first dose of study intervention. | ☐ oui ☐ non |

| | | |
|---|---|---|
| CGFL CENTRE GEORGES FRANÇOIS LECLERC Ensemble, dépassons le cancer | **CRITERES DE SELECTION**<br><br>**ETUDE MK-7339-002-00 LYNK002** | Identité patient<br>(coller étiquette patient) |
| Version 1.0 du 10/03/2015 | Investigateur : | ARC : P. Philippe |

## Critères de non inclusion

.

| | |
|---|---|
| **1.** Participant has a known additional malignancy that is progressing or has required active treatment in the last 5 years.<br>Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, ductal carcinoma in situ, or cervical carcinoma in situ that has undergone potentially curative therapy are not excluded. | ☐ oui ☐ non |
| **2.** Participant has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML. | ☐ oui ☐ non |
| **3.** Participant has persistent toxicities (>CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia. | ☐ oui ☐ non |
| **4.** Participant has known central nervous system (CNS) metastases and/or carcinomatous meningitis.<br>Note: Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression for at least 4 weeks (28 days) by repeat imaging [repeat imaging should be performed during study screening]), clinically stable, and without requirement for steroid treatment for at least 14 days prior to the first dose of study intervention. | ☐ oui ☐ non |
| **5.** Participant has an active infection requiring systemic therapy. | ☐ oui ☐ non |
| **6.** Participant has a history or current evidence of any condition (eg, cytopenia, transfusion-dependent anemia, or thrombocytopenia), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's involvement for the full duration of the study, or is not in the best interest of the participant to be involved, in the opinion of the treating Investigator. | ☐ oui ☐ non |
| **7.** Participant received colony-stimulating factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 28 days prior to the first dose of study intervention. | ☐ oui ☐ non |
| **8.** Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent. | ☐ oui ☐ non |
| **9.** Participant has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study. | ☐ oui ☐ non |

| | |
|---|---|
| **10.** Participant has a known history of human immunodeficiency virus (HIV) infection. Testing for HIV at screening is only required if mandated by local health authority. Refer to Appendix 7 for country-specific requirements. | |
| **11.** Participant has known active hepatitis (ie, Hepatitis B or C)<br>- Active hepatitis B virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result. Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible.<br>- - Participants positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. | ☐ oui ☐ non |
| **12.** Participant is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, malabsorption). | ☐ oui ☐ non |
| **Prior/Concomitant Therapy**<br>**13.** Participant has received prior therapy with olaparib or with any other PARP inhibitor. | ☐ oui ☐ non |
| **14.** Participant has a known hypersensitivity to the components or excipients in olaparib. | ☐ oui ☐ non |
| **15.** Participant is currently receiving either strong (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 2 weeks.<br>*Note: a current list of strong/moderate inhibitors of CYP3A4 can be found at the following website:*<br>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling | ☐ oui ☐ non |
| **16.** Participant is currently receiving either strong (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (eg. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents.<br>*Note: a current list of strong/moderate inducers of CYP3A4 can be found at the following website:*<br>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling | ☐ oui ☐ non |
| **17.** Participant has received previous allogenic bone-marrow transplant or double umbilical cord transplantation (dUCBT). | ☐ oui ☐ non |
| **18.** Participant has received a whole blood transfusion in the last 120 days prior to entry to the study. Packed red blood cells and platelet transfusions are acceptable if not performed within 28 days of the first dose of study intervention. | ☐ oui ☐ non |

| | |
|---|---|
| **Prior/Concurrent Clinical Study Experience**<br>**19.** Participant is currently enrolled in and receiving study therapy, was enrolled in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks (28 days) of the first dose of study intervention<br>Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks (28 days) after the last dose of the previous investigational agent | ☐ oui ☐ non |
| **20.** Participant either had major surgery within 2 weeks of starting study intervention or has not recovered from any effects of any major surgery. | ☐ oui ☐ non |
| **21.** Participant is involved in the planning and/or conduct of the study (applies to both Sponsor staff and/or staff at the study site). | ☐ oui ☐ non |
| **22.** Participant, in the judgement of the Investigator, is unlikely to comply with the study procedures, restrictions, and requirements of the study. | ☐ oui ☐ non |

Date : _____

Signature de l'investigateur : _____